Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Clinical Lymphoma, Myeloma and Leukemia is Scopus-indexed (Q3, CiteScore 2.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 2152-2650Verify ISSN ↗2152-2669Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: About US$3,890 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 83 / 151 | 45th | Q3 |
| Oncology | 273 / 428 | 36th | Q3 |
| Cancer Research | 183 / 233 | 21st | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2010–present, best quartile Q3, CiteScore 2.6.
Clinical Lymphoma, Myeloma and Leukemia is Q3 in Hematology (rank 83 of 151), Q3 in Oncology (rank 273 of 428) and Q4 in Cancer Research (rank 183 of 233), by CiteScore 2025.
Clinical Lymphoma, Myeloma and Leukemia is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.6, which places it in quartile Q3 at the 45th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.615, quartile Q2, with an H-index of 71.
The publisher lists an article processing charge of about US$3,890 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Clinical Lymphoma, Myeloma and Leukemia is published by Elsevier Inc. Its print ISSN is 2152-2650 and its online ISSN is 2152-2669.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Clinical Lymphoma, Myeloma and Leukemia has an h-index of 67 and a 2-year mean of 0.24 citations per paper (OpenAlex). Its Scopus CiteScore is 2.6, quartile Q3. On 2-year citations it ranks #130 of 148 Scopus journals in Hematology.
Clinical Lymphoma, Myeloma and Leukemia published 3,476 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 93 research articles (2026), authors are most often from United States (52.5%), France (5.3%) and China (5.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 3 retracted papers are recorded (0.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.